

# Ornithine Transcarbamylase Deficiency Treatment Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/O5BD24306CF9EN.html>

Date: July 2024

Pages: 60

Price: US\$ 3,250.00 (Single User License)

ID: O5BD24306CF9EN

## Abstracts

Ornithine transcarbamylase (OTC) deficiency is a genetic disorder arising due to inadequate levels of OTC, an enzyme that helps decompose and eliminate unwanted nitrogen from the human body. This process is also known as the urea cycle. Deficiency of this enzyme causes excessive nitrogen accumulation, or hyperammonemia, in the blood. Another perilous effect of this genetic disorder is the secretion of elevated levels of ammonia, which is a notorious neurotoxin. Once it reaches the central nervous system, it induces symptoms such as anorexia and overall lethargy.

This report contains market size and forecasts of Ornithine Transcarbamylase Deficiency Treatment in Global, including the following market information:

Global Ornithine Transcarbamylase Deficiency Treatment Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Ornithine Transcarbamylase Deficiency Treatment market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Oral Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Ornithine Transcarbamylase Deficiency Treatment

include Abbott Laboratories, Nutricia (Danone Group), Mead Johnson (Reckitt Benckiser), Horizon Therapeutics, Nestle, Bausch Health Companies, Ultragenyx Pharmaceutical, Arcturus Therapeutics and Acer Therapeutics. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Ornithine Transcarbamylase Deficiency Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Ornithine Transcarbamylase Deficiency Treatment Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Ornithine Transcarbamylase Deficiency Treatment Market Segment Percentages, by Type, 2021 (%)

Oral

Intravenous

Global Ornithine Transcarbamylase Deficiency Treatment Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Ornithine Transcarbamylase Deficiency Treatment Market Segment Percentages, by Application, 2021 (%)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Ornithine Transcarbamylase Deficiency Treatment Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

## Global Ornithine Transcarbamylase Deficiency Treatment Market Segment Percentages, By Region and Country, 2021 (%)

### North America

US

Canada

Mexico

### Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

### Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

## Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Ornithine Transcarbamylase Deficiency Treatment revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Ornithine Transcarbamylase Deficiency Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Abbott Laboratories

Nutricia (Danone Group)

Mead Johnson (Reckitt Benckiser)

Horizon Therapeutics

Nestle

Bausch Health Companies

Ultragenyx Pharmaceutical

Arcturus Therapeutics

Acer Therapeutics

## Contents

### **1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS**

- 1.1 Ornithine Transcarbamylase Deficiency Treatment Market Definition
- 1.2 Market Segments
  - 1.2.1 Market by Type
  - 1.2.2 Market by Application
- 1.3 Global Ornithine Transcarbamylase Deficiency Treatment Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
  - 1.5.1 Research Methodology
  - 1.5.2 Research Process
  - 1.5.3 Base Year
  - 1.5.4 Report Assumptions & Caveats

### **2 GLOBAL ORNITHINE TRANSCARBAMYLASE DEFICIENCY TREATMENT OVERALL MARKET SIZE**

- 2.1 Global Ornithine Transcarbamylase Deficiency Treatment Market Size: 2021 VS 2028
- 2.2 Global Ornithine Transcarbamylase Deficiency Treatment Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
  - 2.3.1 Market Opportunities & Trends
  - 2.3.2 Market Drivers
  - 2.3.3 Market Restraints

### **3 COMPANY LANDSCAPE**

- 3.1 Top Ornithine Transcarbamylase Deficiency Treatment Players in Global Market
- 3.2 Top Global Ornithine Transcarbamylase Deficiency Treatment Companies Ranked by Revenue
- 3.3 Global Ornithine Transcarbamylase Deficiency Treatment Revenue by Companies
- 3.4 Top 3 and Top 5 Ornithine Transcarbamylase Deficiency Treatment Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Ornithine Transcarbamylase Deficiency Treatment Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Ornithine Transcarbamylase Deficiency Treatment Players in Global Market

3.6.1 List of Global Tier 1 Ornithine Transcarbamylase Deficiency Treatment Companies

3.6.2 List of Global Tier 2 and Tier 3 Ornithine Transcarbamylase Deficiency Treatment Companies

## **4 MARKET SIGHTS BY PRODUCT**

4.1 Overview

4.1.1 by Type - Global Ornithine Transcarbamylase Deficiency Treatment Market Size Markets, 2021 & 2028

4.1.2 Oral

4.1.3 Intravenous

4.2 By Type - Global Ornithine Transcarbamylase Deficiency Treatment Revenue & Forecasts

4.2.1 By Type - Global Ornithine Transcarbamylase Deficiency Treatment Revenue, 2017-2022

4.2.2 By Type - Global Ornithine Transcarbamylase Deficiency Treatment Revenue, 2023-2028

4.2.3 By Type - Global Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share, 2017-2028

## **5 SIGHTS BY APPLICATION**

5.1 Overview

5.1.1 By Application - Global Ornithine Transcarbamylase Deficiency Treatment Market Size, 2021 & 2028

5.1.2 Hospital Pharmacies

5.1.3 Retail Pharmacies

5.1.4 Online Pharmacies

5.2 By Application - Global Ornithine Transcarbamylase Deficiency Treatment Revenue & Forecasts

5.2.1 By Application - Global Ornithine Transcarbamylase Deficiency Treatment Revenue, 2017-2022

5.2.2 By Application - Global Ornithine Transcarbamylase Deficiency Treatment Revenue, 2023-2028

5.2.3 By Application - Global Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share, 2017-2028

## **6 SIGHTS BY REGION**

6.1 By Region - Global Ornithine Transcarbamylase Deficiency Treatment Market Size, 2021 & 2028

6.2 By Region - Global Ornithine Transcarbamylase Deficiency Treatment Revenue & Forecasts

6.2.1 By Region - Global Ornithine Transcarbamylase Deficiency Treatment Revenue, 2017-2022

6.2.2 By Region - Global Ornithine Transcarbamylase Deficiency Treatment Revenue, 2023-2028

6.2.3 By Region - Global Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Ornithine Transcarbamylase Deficiency Treatment Revenue, 2017-2028

6.3.2 US Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028

6.3.3 Canada Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028

6.3.4 Mexico Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Ornithine Transcarbamylase Deficiency Treatment Revenue, 2017-2028

6.4.2 Germany Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028

6.4.3 France Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028

6.4.4 U.K. Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028

6.4.5 Italy Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028

6.4.6 Russia Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028

6.4.7 Nordic Countries Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028

6.4.8 Benelux Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Ornithine Transcarbamylase Deficiency Treatment Revenue, 2017-2028

6.5.2 China Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028



6.5.3 Japan Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028

6.5.4 South Korea Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028

6.5.5 Southeast Asia Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028

6.5.6 India Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Ornithine Transcarbamylase Deficiency Treatment Revenue, 2017-2028

6.6.2 Brazil Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028

6.6.3 Argentina Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Revenue, 2017-2028

6.7.2 Turkey Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028

6.7.3 Israel Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028

6.7.4 Saudi Arabia Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028

6.7.5 UAE Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028

## **7 PLAYERS PROFILES**

7.1 Abbott Laboratories

7.1.1 Abbott Laboratories Corporate Summary

7.1.2 Abbott Laboratories Business Overview

7.1.3 Abbott Laboratories Ornithine Transcarbamylase Deficiency Treatment Major Product Offerings

7.1.4 Abbott Laboratories Ornithine Transcarbamylase Deficiency Treatment Revenue in Global Market (2017-2022)

7.1.5 Abbott Laboratories Key News

7.2 Nutricia (Danone Group)

7.2.1 Nutricia (Danone Group) Corporate Summary

7.2.2 Nutricia (Danone Group) Business Overview

7.2.3 Nutricia (Danone Group) Ornithine Transcarbamylase Deficiency Treatment Major Product Offerings

7.2.4 Nutricia (Danone Group) Ornithine Transcarbamylase Deficiency Treatment Revenue in Global Market (2017-2022)

7.2.5 Nutricia (Danone Group) Key News

7.3 Mead Johnson (Reckitt Benckiser)

7.3.1 Mead Johnson (Reckitt Benckiser) Corporate Summary

7.3.2 Mead Johnson (Reckitt Benckiser) Business Overview

7.3.3 Mead Johnson (Reckitt Benckiser) Ornithine Transcarbamylase Deficiency Treatment Major Product Offerings

7.3.4 Mead Johnson (Reckitt Benckiser) Ornithine Transcarbamylase Deficiency Treatment Revenue in Global Market (2017-2022)

7.3.5 Mead Johnson (Reckitt Benckiser) Key News

7.4 Horizon Therapeutics

7.4.1 Horizon Therapeutics Corporate Summary

7.4.2 Horizon Therapeutics Business Overview

7.4.3 Horizon Therapeutics Ornithine Transcarbamylase Deficiency Treatment Major Product Offerings

7.4.4 Horizon Therapeutics Ornithine Transcarbamylase Deficiency Treatment Revenue in Global Market (2017-2022)

7.4.5 Horizon Therapeutics Key News

7.5 Nestle

7.5.1 Nestle Corporate Summary

7.5.2 Nestle Business Overview

7.5.3 Nestle Ornithine Transcarbamylase Deficiency Treatment Major Product Offerings

7.5.4 Nestle Ornithine Transcarbamylase Deficiency Treatment Revenue in Global Market (2017-2022)

7.5.5 Nestle Key News

7.6 Bausch Health Companies

7.6.1 Bausch Health Companies Corporate Summary

7.6.2 Bausch Health Companies Business Overview

7.6.3 Bausch Health Companies Ornithine Transcarbamylase Deficiency Treatment Major Product Offerings

7.6.4 Bausch Health Companies Ornithine Transcarbamylase Deficiency Treatment Revenue in Global Market (2017-2022)

7.6.5 Bausch Health Companies Key News

7.7 Ultragenyx Pharmaceutical

7.7.1 Ultragenyx Pharmaceutical Corporate Summary

7.7.2 Ultragenyx Pharmaceutical Business Overview

7.7.3 Ultragenyx Pharmaceutical Ornithine Transcarbamylase Deficiency Treatment

## Major Product Offerings

7.7.4 Ultragenyx Pharmaceutical Ornithine Transcarbamylase Deficiency Treatment Revenue in Global Market (2017-2022)

7.7.5 Ultragenyx Pharmaceutical Key News

## 7.8 Arcturus Therapeutics

7.8.1 Arcturus Therapeutics Corporate Summary

7.8.2 Arcturus Therapeutics Business Overview

7.8.3 Arcturus Therapeutics Ornithine Transcarbamylase Deficiency Treatment Major Product Offerings

7.8.4 Arcturus Therapeutics Ornithine Transcarbamylase Deficiency Treatment Revenue in Global Market (2017-2022)

7.8.5 Arcturus Therapeutics Key News

## 7.9 Acer Therapeutics

7.9.1 Acer Therapeutics Corporate Summary

7.9.2 Acer Therapeutics Business Overview

7.9.3 Acer Therapeutics Ornithine Transcarbamylase Deficiency Treatment Major Product Offerings

7.9.4 Acer Therapeutics Ornithine Transcarbamylase Deficiency Treatment Revenue in Global Market (2017-2022)

7.9.5 Acer Therapeutics Key News

## **8 CONCLUSION**

## **9 APPENDIX**

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. Ornithine Transcarbamylase Deficiency Treatment Market Opportunities & Trends in Global Market

Table 2. Ornithine Transcarbamylase Deficiency Treatment Market Drivers in Global Market

Table 3. Ornithine Transcarbamylase Deficiency Treatment Market Restraints in Global Market

Table 4. Key Players of Ornithine Transcarbamylase Deficiency Treatment in Global Market

Table 5. Top Ornithine Transcarbamylase Deficiency Treatment Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Ornithine Transcarbamylase Deficiency Treatment Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Ornithine Transcarbamylase Deficiency Treatment Revenue Share by Companies, 2017-2022

Table 8. Global Companies Ornithine Transcarbamylase Deficiency Treatment Product Type

Table 9. List of Global Tier 1 Ornithine Transcarbamylase Deficiency Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Ornithine Transcarbamylase Deficiency Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Ornithine Transcarbamylase Deficiency Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Ornithine Transcarbamylase Deficiency Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Ornithine Transcarbamylase Deficiency Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Ornithine Transcarbamylase Deficiency Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Ornithine Transcarbamylase Deficiency Treatment

Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Ornithine Transcarbamylase Deficiency Treatment Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2023-2028

Table 30. Abbott Laboratories Corporate Summary

Table 31. Abbott Laboratories Ornithine Transcarbamylase Deficiency Treatment Product Offerings

Table 32. Abbott Laboratories Ornithine Transcarbamylase Deficiency Treatment Revenue (US\$, Mn), (2017-2022)

Table 33. Nutricia (Danone Group) Corporate Summary

Table 34. Nutricia (Danone Group) Ornithine Transcarbamylase Deficiency Treatment Product Offerings

Table 35. Nutricia (Danone Group) Ornithine Transcarbamylase Deficiency Treatment Revenue (US\$, Mn), (2017-2022)

Table 36. Mead Johnson (Reckitt Benckiser) Corporate Summary

Table 37. Mead Johnson (Reckitt Benckiser) Ornithine Transcarbamylase Deficiency Treatment Product Offerings

Table 38. Mead Johnson (Reckitt Benckiser) Ornithine Transcarbamylase Deficiency Treatment Revenue (US\$, Mn), (2017-2022)

Table 39. Horizon Therapeutics Corporate Summary

Table 40. Horizon Therapeutics Ornithine Transcarbamylase Deficiency Treatment Product Offerings

Table 41. Horizon Therapeutics Ornithine Transcarbamylase Deficiency Treatment Revenue (US\$, Mn), (2017-2022)

Table 42. Nestle Corporate Summary

Table 43. Nestle Ornithine Transcarbamylase Deficiency Treatment Product Offerings

Table 44. Nestle Ornithine Transcarbamylase Deficiency Treatment Revenue (US\$, Mn), (2017-2022)

Table 45. Bausch Health Companies Corporate Summary

Table 46. Bausch Health Companies Ornithine Transcarbamylase Deficiency Treatment Product Offerings

Table 47. Bausch Health Companies Ornithine Transcarbamylase Deficiency Treatment Revenue (US\$, Mn), (2017-2022)

Table 48. Ultragenyx Pharmaceutical Corporate Summary

Table 49. Ultragenyx Pharmaceutical Ornithine Transcarbamylase Deficiency Treatment Product Offerings

Table 50. Ultragenyx Pharmaceutical Ornithine Transcarbamylase Deficiency Treatment Revenue (US\$, Mn), (2017-2022)

Table 51. Arcturus Therapeutics Corporate Summary

Table 52. Arcturus Therapeutics Ornithine Transcarbamylase Deficiency Treatment Product Offerings

Table 53. Arcturus Therapeutics Ornithine Transcarbamylase Deficiency Treatment Revenue (US\$, Mn), (2017-2022)

Table 54. Acer Therapeutics Corporate Summary

Table 55. Acer Therapeutics Ornithine Transcarbamylase Deficiency Treatment Product Offerings

Table 56. Acer Therapeutics Ornithine Transcarbamylase Deficiency Treatment Revenue (US\$, Mn), (2017-2022)

## List Of Figures

### LIST OF FIGURES

- Figure 1. Ornithine Transcarbamylase Deficiency Treatment Segment by Type in 2021
- Figure 2. Ornithine Transcarbamylase Deficiency Treatment Segment by Application in 2021
- Figure 3. Global Ornithine Transcarbamylase Deficiency Treatment Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Ornithine Transcarbamylase Deficiency Treatment Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Ornithine Transcarbamylase Deficiency Treatment Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Ornithine Transcarbamylase Deficiency Treatment Revenue in 2021
- Figure 8. By Type - Global Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share, 2017-2028
- Figure 12. US Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share, 2017-2028
- Figure 16. Germany Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn),

2017-2028

Figure 20. Russia Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share, 2017-2028

Figure 24. China Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2028

Figure 28. India Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share, 2017-2028

Figure 30. Brazil Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share, 2017-2028

Figure 33. Turkey Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Ornithine Transcarbamylase Deficiency Treatment Revenue, (US\$, Mn), 2017-2028

Figure 37. Abbott Laboratories Ornithine Transcarbamylase Deficiency Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Nutricia (Danone Group) Ornithine Transcarbamylase Deficiency Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)



Figure 39. Mead Johnson (Reckitt Benckiser) Ornithine Transcarbamylase Deficiency Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Horizon Therapeutics Ornithine Transcarbamylase Deficiency Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Nestle Ornithine Transcarbamylase Deficiency Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Bausch Health Companies Ornithine Transcarbamylase Deficiency Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Ultragenyx Pharmaceutical Ornithine Transcarbamylase Deficiency Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Arcturus Therapeutics Ornithine Transcarbamylase Deficiency Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Acer Therapeutics Ornithine Transcarbamylase Deficiency Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

## I would like to order

Product name: Ornithine Transcarbamylase Deficiency Treatment Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/O5BD24306CF9EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O5BD24306CF9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

